CODX logo

CODX
Co-Diagnostics Inc

31,967
Mkt Cap
$17.29M
Volume
13,092.00
52W High
$46.50
52W Low
$2.20
PE Ratio
-0.09
CODX Fundamentals
Price
$2.49
Prev Close
$2.35
Open
$2.40
50D MA
$5.49
Beta
1.42
Avg. Volume
123,171.60
EPS (Annual)
-$37.22
P/B
0.10
Rev/Employee
$5,833.70
$4.84
Loading...
Loading...
News
all
press releases
Will Community Health's $450M Hospital Divestment Reduce Debt Burden?
CYH plans to sell Crestwood Medical Center for $450M, a deal topping its market value and aimed at easing the hospital operator's heavy debt load.
Zacks·25d ago
News Placeholder
More News
News Placeholder
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen...
PR Newswire·1mo ago
News Placeholder
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
Zacks·2mo ago
News Placeholder
CODX Stock Plunges To All-Time Lows On 1-for-30 Reverse Stock Split Approval
After the reverse split becomes effective, Co-Diagnostics will have around 2.1 million outstanding shares.
Stocktwits·2mo ago
News Placeholder
Co-Diagnostics Announces Reverse Stock Split
Co-Diagnostics Announces Reverse Stock Split Co-Diagnostics Announces Reverse Stock Split PR Newswire SALT LAKE CITY, Dec. 30, 2025 SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ --Co-Diagnostics, Inc...
PR Newswire·2mo ago
News Placeholder
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies PR Newswire...
PR Newswire·2mo ago
News Placeholder
Co-Diagnostics Performs Analysis of Influenza Co-Primers to Confirm Reactivity Against Flu A H3N2 Mutation
Co-Diagnostics Performs Analysis of Influenza Co-Primers to Confirm Reactivity Against Flu A H3N2 Mutation Co-Diagnostics Performs Analysis of Influenza Co-Primers to Confirm Reactivity Against Flu A...
PR Newswire·2mo ago
News Placeholder
Co-Diagnostics to Present on Co-Dx PCR Platform and AI Integration at Point-of-Care Testing 2025
Co-Diagnostics to Present on Co-Dx PCR Platform and AI Integration at Point-of-Care Testing 2025 Co-Diagnostics to Present on Co-Dx PCR Platform and AI Integration at Point-of-Care Testing 2025 PR...
PR Newswire·2mo ago
News Placeholder
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India PR Newswire SALT LAKE CITY, Dec. 9, 2025 Ongoing...
PR Newswire·2mo ago
News Placeholder
CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
<
1
2
...
>

Latest CODX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.